Effect of statin use during hospitalization for intracerebral hemorrhage on mortality and discharge disposition

JAMA Neurology

Volumn 71, Issue 11, 2014, Pages 1364-1371

  Flint, Alexander C ^a   Conell, Carol ^b   Rao, Vivek A ^a   Klingman, Jeff G ^a   Sidney, Stephen ^b   Johnston, S Claiborne ^c   Hemphill, J Claude ^d   Kamel, Hooman ^e   Davis, Stephen M ^f   Donnan, Geoffrey A ^f  

^a KAISER PERMANENTE   (United States)

^b DIVISION OF RESEARCH   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; BRAIN HEMORRHAGE; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EXPOSURE; DRUG MEGADOSE; DRUG USE; ELECTRONIC MEDICAL RECORD; FEMALE; GLASGOW COMA SCALE; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; CEREBRAL HEMORRHAGE; MIDDLE AGED; RISK ASSESSMENT; STROKE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CEREBRAL HEMORRHAGE; COHORT STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INPATIENTS; MALE; MIDDLE AGED; PATIENT DISCHARGE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; STROKE; TREATMENT OUTCOME;

EID: 84919395077     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.2124     Document Type: Conference Paper

References (35)

1. Amarenco P, Bogousslavsky J, Callahan A III, et al Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549-559.
2. Flint AC, Kamel H, Navi BB, et al. Statin use during ischemic stroke hospitalization is strongly associated with improved poststroke survival. Stroke. 2012;43(1):147-154.
3. Flint AC, Kamel H, Navi BB, et al. Inpatient statin use predicts improved ischemic stroke discharge disposition. Neurology. 2012;78(21):1678-1683.
4. Blanco M, Nombela F, Castellanos M, et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology. 2007;69 (9):904-910.
5. Aronowski J, Zhao X. Molecular pathophysiology of cerebral hemorrhage: secondary brain injury. Stroke. 2011;42(6):1781-1786.
6. Xi G, Keep RF, Hoff JT. Mechanisms of brain injury after intracerebral haemorrhage. Lancet Neurol. 2006;5(1):53-63.
7. Antonopoulos AS, Margaritis M, Lee R, Channon K, Antoniades C. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des. 2012;18(11):1519-1530.
8. de Oliveira CV, Funck VR, Pereira LM, et al. Atorvastatin withdrawal elicits oxidative/nitrosative damage in the rat cerebral cortex. Pharmacol Res. 2013;71:1-8.
9. McKinney JS, Kostis WJ. Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials. Stroke. 2012;43(8):2149-2156.
10. Hackam DG, Woodward M, Newby LK, et al. Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis. Circulation. 2011;124(20):2233-2242.
11. Goldstein LB, Amarenco P, Szarek M, et al SPARCL Investigators. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology. 2008;70(24, pt 2):2364-2370.
12. Spence JD. Statins do not cause intracerebral hemorrhage. Neurology. 2012;79(11):1076-1077.
13. Goldstein LB. Statin therapy should be discontinued in patients with intracerebral hemorrhage. Stroke. 2013;44(7):2058-2059.
14. Bustamante A, Montaner J. Statin therapy should not be discontinued in patients with intracerebral hemorrhage. Stroke. 2013;44(7):2060-2061.
15. Scheitz JF, Nolte CH, Endres M. Should statins be paused or discontinued after thrombolysis or acute intracerebral hemorrhage? no! Stroke. 2013;44(5):1472-1476.
16. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285 (18):2370-2375.
17. Hernán MA, Robins JM. Instruments for causal inference: an epidemiologist's dream? Epidemiology. 2006;17(4):360-372.
18. BrookhartMA,Wang PS, Solomon DH, Schneeweiss S. Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology. 2006;17(3):268-275.
19. Angrist JD, Imbens GW, Rubin DB. Identification of causal effects using instrumental variables. J Am Stat Assoc. 1996;91(434):444-455. doi:10.2307/2291634.
20. Newhouse JP, McClellan M. Econometrics in outcomes research: the use of instrumental variables. Annu Rev Public Health. 1998;19(1):17-34.
21. Rassen JA, Mittleman MA, Glynn RJ, Alan Brookhart M, Schneeweiss S. Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention. Eur Heart J. 2010;31(5):561-572.
22. Brookhart MA, Rassen JA, Wang PS, Dormuth C, Mogun H, Schneeweiss S. Evaluating the validity of an instrumental variable study of neuroleptics: can between-physician differences in prescribing patterns be used to estimate treatment effects? Med Care. 2007;45(10)(suppl 2):S116-S122.
23. Lévesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ. 2010;340:b5087.
24. Lee JG, Koh SJ, Yoo SY, et al. Characteristics of subjects with very low serum low-density lipoprotein cholesterol and the risk for intracerebral hemorrhage. Korean J Intern Med. 2012;27(3):317-326.
25. Scheitz JF, Seiffge DJ, Tütüncü S, et al. Dose-related effects of statins on symptomatic intracerebral hemorrhage and outcome after thrombolysis for ischemic stroke. Stroke. 2014;45 (2):509-514.
26. Rocco A, Sykora M, Ringleb P, Diedler J. Impact of statin use and lipid profile on symptomatic intracerebral haemorrhage, outcome and mortality after intravenous thrombolysis in acute stroke. Cerebrovasc Dis. 2012;33(4):362-368.
27. Nardi K, Engelter S, Strbian D, et al Lipid Profile in Thrombolysis Study Group. Lipid profiles and outcome in patients treated by intravenous thrombolysis for cerebral ischemia. Neurology. 2012;79(11):1101-1108.
28. Naval NS, Abdelhak TA, Zeballos P, Urrunaga N, MirskiMA, Carhuapoma JR. Prior statin use reduces mortality in intracerebral hemorrhage. Neurocrit Care. 2008;8(1):6-12.
29. Tapia-Pérez JH, Rupa R, Zilke R, Gehring S, Voellger B, Schneider T. Continued statin therapy could improve the outcome after spontaneous intracerebral hemorrhage. Neurosurg Rev. 2013;36(2):279-287, discussion 287.
30. Lei C,Wu B, LiuM, Chen Y. Association between statin use and intracerebral hemorrhage: a systematic review and meta-analysis. Eur J Neurol. 2014;21(2):192-198.
31. Biffi A, DevanWJ, Anderson CD, et al. Statin use and outcome after intracerebral hemorrhage: case-control study and meta-analysis. Neurology. 2011;76(18):1581-1588.
32. Naval NS, Abdelhak TA, Urrunaga N, Zeballos P, MirskiMA, Carhuapoma JR. An association of prior statin use with decreased perihematomal edema. Neurocrit Care. 2008;8(1):13-18.
33. Indraswari F, Wang H, Lei B, et al. Statins improve outcome in murine models of intracranial hemorrhage and traumatic brain injury: a translational approach. J Neurotrauma. 2012;29(7):1388-1400.
34. Karki K, Knight RA, Han Y, et al. Simvastatin and atorvastatin improve neurological outcome after experimental intracerebral hemorrhage. Stroke. 2009;40(10):3384-3389.
35. Lu D, Qu C, Goussev A, et al. Statins increase neurogenesis in the dentate gyrus, reduce delayed neuronal death in the hippocampal CA3 region, and improve spatial learning in rat after traumatic brain injury. J Neurotrauma. 2007;24(7):1132-1146.